<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03794544</url>
  </required_header>
  <id_info>
    <org_study_id>D9108C00002</org_study_id>
    <nct_id>NCT03794544</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Subjects With Resectable, Early-stage (I [&gt; 2 cm] to IIIA) Non-small Cell Lung Cancer (NeoCOAST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study D9108C00002 (NeoCOAST) is a platform study assessing the effectiveness and safety of
      neoadjuvant durvalumab alone or in combination with novel agents in subjects with resectable,
      early-stage (Stage I [&gt;2cm] to IIIA) non-small cell lung cancer (NSCLC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2019</start_date>
  <completion_date type="Anticipated">March 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 8, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be enrolled and randomized into a durvalumab monotherapy arm or into a durvalumab plus other novel therapy arms. Up to approximately 25 sites globally will participate in this study. New treatment arms may be added in the future. Subjects will be treated with a single durvalumab dose alone or in combination with other agents. After the single cycle treatment period patients will have the standard surgical resection planned. All subjects will have a post-resection monitoring visit. Study treatment will be discontinued upon disease progression, unacceptable toxicity, or other investigators' reasons.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Pathological Response rate</measure>
    <time_frame>Major Pathological Response will be done in the resected specimen. Surgery is planned to take place within 14 days after the 4 weeks treatment period.</time_frame>
    <description>Assess the antitumor activity of durvalumab alone and/or in combination with novel agents</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility to surgery within the 14 days window period is a dichotomic variable: patients will have or will not have the tumor surgical resection done.</measure>
    <time_frame>Surgery is planned to take place within 14 days after the 4 weeks treatment period.</time_frame>
    <description>Assess the feasibility of receiving the planned surgical resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs and SAEs</measure>
    <time_frame>Up to 126 days after C1D1</time_frame>
    <description>Assess the safety and tolerability of durvalumab alone and/or in combination with novel agents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological Complete Response rate</measure>
    <time_frame>Pathological Complete Response will be done in the resected specimen. Surgery is planned to take place within 14 days after the 4 weeks treatment period.</time_frame>
    <description>Assess the antitumor activity of durvalumab alone and/or in combination with novel agents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of durvalumab or novel agents in plasma or serum.</measure>
    <time_frame>Up to 126 days after C1D1</time_frame>
    <description>To describe the PK of durvalumab alone and/or in combination with novel agents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADA incidence of durvalumab or novel biologic agents.</measure>
    <time_frame>Up to 126 days after C1D1</time_frame>
    <description>To assess the immunogenicity of durvalumab alone or in combination with novel agents
To assess the immunogenicity of novel biologic agents in combination with durvalumab</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Resectable</condition>
  <condition>Early-stage</condition>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Arm A: Durvalumab monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>durvalumab IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Durvalumab + Oleclumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>durvalumab IV and oleclumab IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Durvalumab + Monalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>durvalumab IV and monalizumab IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D: Durvalumab + Danvatirsen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>danvatirsen IV and durvalumab IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Durvalumab</description>
    <arm_group_label>Arm A: Durvalumab monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Durvalumab + Oleclumab</intervention_name>
    <description>Durvalumab + Oleclumab</description>
    <arm_group_label>Arm B: Durvalumab + Oleclumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Durvalumab + Monalizumab</intervention_name>
    <description>Durvalumab + Monalizumab</description>
    <arm_group_label>Arm C: Durvalumab + Monalizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Durvalumab + Danvatirsen</intervention_name>
    <description>Durvalumab + Danvatirsen</description>
    <arm_group_label>Arm D: Durvalumab + Danvatirsen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Cytologically and/or histologically-documented NSCLC

               1. Stage I (&gt; 2 cm) to IIIA (for subjects with N2 disease, only those with 1 single
                  nodal station ≤ 3 cm are eligible) NSCLC according to the 8th edition of American
                  Joint Committee on Cancer staging classification

               2. Amenable to complete surgical resection

               3. Have not received any other therapy for this condition

          2. Age ≥18 years old

          3. Predicted FEV1 ≥ 50%

          4. Predicted DLCO ≥ 50%

          5. ECOG 0 or 1

          6. Adequate organ function

        Exclusion Criteria:

          1. Subjects with small-cell lung cancer or mixed small-cell lung cancer

          2. Subjects who require or may require pneumonectomy

          3. Prior treatment with PD-L1, PD-L1, or CTLA-4 inhibitors

          4. Current or prior use of immunosuppressive medication within 14 days before the first
             dose of study drug.

          5. Active or prior documented autoimmune or inflammatory disorders. The following are
             exceptions to this criterion:

               1. Subjects with vitiligo or alopecia

               2. Subjects with hypothyroidism on hormone replacement

               3. Any chronic skin condition that does not require systemic therapy

               4. Subjects without active disease in the last 5 years may be included but only
                  after consultation with the study physician

               5. Subjects with celiac disease controlled by diet alone

          6. Pregnant or breast-feeding female

          7. Major surgical procedure within prior 30 days

          8. History of active primary immunodeficiency

          9. Active infection including tuberculosis, hepatitis B, hepatitis C, or HIV

         10. QTc interval (QTc) ≥ 470 ms

         11. Uncontrolled intercurrent illness that would limit compliance with study requirement,
             substantially increase risk of incurring AEs or compromise the ability of the subject
             to give written informed consent

         12. Receipt of live attenuated vaccination within 30 days prior to study entry

         13. History of another primary malignancy except for:

               1. Curative-treated malignancy with no known active disease &gt; 2 years before
                  enrollment on the study

               2. Curative-treated non-melanoma skin cancer and/or carcinoma in-situ
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>102 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leesburg</city>
        <state>Florida</state>
        <zip>34748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55445</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille Cedex 9</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulouse CEDEX 09</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Catania</city>
        <zip>95125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>A Coruña</city>
        <zip>15001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 10, 2018</study_first_submitted>
  <study_first_submitted_qc>January 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2019</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoadjuvant</keyword>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>Cancer</keyword>
  <keyword>Lung</keyword>
  <keyword>Resectable</keyword>
  <keyword>Early-stage</keyword>
  <keyword>Stage I</keyword>
  <keyword>Stage II</keyword>
  <keyword>Stage IIIA</keyword>
  <keyword>Durvalumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

